Myriad Genetics inches closer to acquiring Crescendo Bioscience

Myriad Genetics ($MYGN) is inching closer to snatching up molecular diagnostic test maker Crescendo Bioscience. Utah-based Myriad first made its interest known back in 2011, when it invested $25 million into Crescendo with a three-year option to buy the South San Francisco company. Since then, Crescendo has achieved a number of milestones, such as winning Medicare coverage over the summer for its Vectra DA test for rheumatoid arthritis. Myriad said in a regulatory filing that in the wake of Crescendo meeting a "minimum revenue milestone," it has notified executives "of its preliminary, non-binding interest in completing the merger," subject to the necessary due diligence. Regulatory filing

Suggested Articles

The randomized, blinded study showed statistically significant improvements in assessments of inattention and brain activity.

U.K.-based surgery robot developer CMR Surgical has begun rolling out its Versius platform to the NHS, completing its first procedures in Europe.

The former Fierce 15 winner’s SuperMap program was cleared to guide electrophysiologists in the treatment of stable and transient arrhythmias.